Vanda Pharmaceuticals Inc.
VNDA
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment ofā¦ read more
Healthcare
Biotechnology
20 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$5.10
Price-1.55%
-$0.08
1Y
Price
Market Cap
$306.691m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-52.0%
EBITDA Margin-40.1%
Net Profit Margin-56.5%
Free Cash Flow Margin-52.0%
EBITDA Margin-40.1%
Net Profit Margin-56.5%
Free Cash Flow MarginRevenue
$217.782m
+6.7%
1y CAGR-4.8%
3y CAGR-4.9%
5y CAGREarnings
-$239.547m
-345.5%
1y CAGR-419.6%
3y CAGR-335.0%
5y CAGREPS
-$4.05
-343.7%
1y CAGR-435.8%
3y CAGR-347.1%
5y CAGRBook Value
$280.765m
$433.525m
Assets$152.760m
Liabilities$13.073m
DebtDebt to Assets
3.0%
-0.1x
Debt to EBITDAFree Cash Flow
-$127.296m
-410.6%
1y CAGR-233.9%
3y CAGR-188.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company